A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 164, Issue , 2016, Pages 254-257

  Muris, Anne Hilde ^a,b   Rolf, Linda ^a,b   Broen, Kelly ^b   Hupperts, Raymond ^a,b   Damoiseaux, Jan ^a   Smolders, Joost ^b,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

25 Hydroxyvitamin D; Disability; Relapsing remitting multiple sclerosis; Secondary progressive multiple sclerosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; VITAMIN D;

ADULT; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PROGNOSIS; TIME FACTOR;

ADULT; BIOMARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VITAMIN D;

EID: 84949023787     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2015.11.009     Document Type: Review

References (19)

1. [1] Compston, A., Coles, A., Multiple sclerosis. Lancet 372 (2015), 1502–1517.
2. [2] Weinshenker, B.G., Bass, B., Rice, G.P., The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:Pt 1 (2015), 133–146.
3. [3] Lublin, F.D., Reingold, S.C., Cohen, J.A., Defining the clinical course of multiple sclerosis: the revisions. Neurology 83 (2013), 278–286.
4. [4] Lublin, F.D., Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 46 (2015), 907–911.
5. [5] Tremlett, H., Paty, D., Devonshire, V., Disability progression in multiple sclerosis is slower than previously reported. Neurology 66 (2015), 172–177.
6. [6] Leray, E., Yaouanq, J., Le, P.E., et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 133 (2010), 1900–1913.
7. [7] Kamm, C.P., Uitdehaag, B.M., Polman, C.H., Multiple sclerosis: current knowledge and future outlook. Eur. Neurol. 72 (2015), 132–141.
8. [8] Ontaneda, D., Fox, R.J., Chataway, J., Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 14 (2015), 208–223.
9. [9] Simpson, S. Jr, Taylor, B., Blizzard, L., Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 68 (2015), 193–203.
10. [10] Smolders, J., Menheere, P., Kessels, A., Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 14 (2015), 1220–1224.
11. [11] Ascherio, A., Munger, K.L., White, R., Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 71 (2015), 306–314.
12. [12] van der Mei, I.A., Ponsonby, A.L., Dwyer, T., Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 254 (2015), 581–590.
13. [13] Fitzgerald, K.C., Munger, K.L., Kochert, K., Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta -1b. JAMA Neurol., 2015, 1–8.
14. [14] McDonald, W.I., Compston, A., Edan, G., Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2015), 121–127.
15. [15] Polman, C.H., Reingold, S.C., Edan, G., Diagnostic criteria for multiple sclerosis: revisions to the “McDonald Criteria”. Ann. Neurol. 58 (2005), 840–846.
16. [16] Kurtzke, J.F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (2015), 1444–1452.
17. [17] Koch, M., Kingwell, E., Rieckmann, P., The natural history of secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 81 (2015), 1039–1043.
18. [18] Edan, G., Kappos, L., Montalban, X., Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J. Neurol. Neurosurg. Psychiatry 85 (2015), 1183–1189.
19. [19] Zastepa, E., Fitz-Gerald, L., Hallett, M., Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS. Neurology 82 (2015), 681–690.